New feature! International drug price search portal. Compare what you're paying with other countries around the world at www.drugpricelookup.com. We also offer this feature to physician offices at no charge.
Canadian pharmacies expect to see an even bigger rebound in sales for Canadian drugs in the coming months, when many Americans will hit the so-called "doughnut hole" in the Medicare plan, the gap where there is no reimbursement. Seniors must then pay full price for all of their medications.
And to make things worse, in 2009 the Medicare plan premiums and deductibles rose, which combined with larger copays, will amount to a substantial increase in cost for elderly Americans.
Many thousands are also discovering that it is now less expensive to buy brand name drugs overseas and/or U.S. generics than to utilize the Medicare Part D Plan. In this case, their annual expenses are less than what they would have spent with Medicare. Most retain their Part D Plan as insurance should they need to regain access to the system at a later date and avoid any penalties.
It's going to be a no-brainer for Canada. "We've already done studies that show 80 per cent of the time Canadian drugs are cheaper than Medicare drugs. The outlook is rosey." Full article See comparison
Patient safety is our primary concern, however, a prescription drug that is not affordable is neither safe nor effective. The following research shows beyond a doubt how drug companies, in conjunction with the FDA, have set out to deceive physicians and patients on the issue of safety.
Europe has been reimporting or "parallel trading" prescription drugs since 1985 without any reported ill effects. As with our Canadian pharmacy, our confidence level with European and other pharmacies is extremely high.
What the FDA and drug companies don't want you to know is, many of the medications we consume in the U.S. have been researched, developed, and manufactured in other countires for quite some time. USA Today Oct. 19, 2004. The FDA is well aware of the safety of these medications since they are required to inspect these plants every two years.
Major drug companies are now manufacturing for the U.S. market, in other countries:
"FDA Commissioner Andrew von Eschenbach on Thursday laid out a plan to place more than 60 food and drug regulators worldwide over the next year, with a particular focus on India, Latin America and the Middle East." USA Today Oct.16, 2008
"India today has the largest number of US Food & Drug Administration (FDA)-approved drug manufacturing facilities outside the US. Drug Master Files (DMFs), which have to be approved by the FDA before a drug can enter the US market, filed by Indian companies total 126 - higher than Spain, Italy, China and Israel put together." Asia Times May 11, 2005
"Cipla's manufacturing facilities (India) have been approved by the following regulatory authorities:"
Food and Drug Administration (FDA), USA
Medicines and Healthcare products Regulatory Agency (MHRA), UK
Therapeutic Goods Administration (TGA), Australia
Medicines Control Council (MCC), South Africa
National Institute of Pharmacy (NIP), Hungary
Pharamaceutical Inspection Convention (PIC), Germany
World Health Organisation (WHO) Department of Health, Canada
State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil